Methotrexate in advanced bladder cancer.
Over a period of 9 years (1970 to 1979), 64 patients with advanced local or metastatic bladder cancer were treated with methotrexate by one of three regimens. Response rates of 50% and over were noted with two of the three regimens studied. The response rate was greater for metastatic disease (44%) than for local disease (16%). Toxicity at the dosage used was minimal provided renal function was satisfactory.
D001859:Bone Neoplasms / Q000188:drug therapy / Q000556:secondary; D004334:Drug Administration Schedule; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000556:secondary; D008727:Methotrexate / Q000009:adverse effects / Q000627:therapeutic use*; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy; D011379:Prognosis; D012189:Retrospective Studies; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy*
D008727:Methotrexate